Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma

References

• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;316(24):1493–1498. doi:10.1056/NEJM198706113162401
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the nordic lymphoma group. Blood. 2008;112(7):2687–2693. doi:10.1182/blood-2008-03-147025
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918–3927. doi:10.1200/JCO.2003.10.023
   PubMed Web of Science ®Google Scholar
• d‘Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–3099. doi:10.1200/JCO.2011.40.2719
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. doi:10.1056/NEJM199512073332305
   PubMed Web of Science ®Google Scholar
• Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20(5):684–689. doi:10.1016/j.bbmt.2014.01.025
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the european blood and marrow transplantation registry. Haematologica. 2008;93(12):1837–1842. doi:10.3324/haematol.13273
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Okoroji GJ, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin’s lymphoma in patients >65 years of age. Ann Oncol. 2008;19(6):1166–1171. doi:10.1093/annonc/mdm608
   PubMed Web of Science ®Google Scholar
• Dahi PB, Tamari R, Devlin SM, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–2009. doi:10.1016/j.bbmt.2014.08.019
   PubMed Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma ­undergoing high-dose therapy with autologous ­hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–1053. doi:10.1016/j.bbmt.2015.02.005
   PubMed Web of Science ®Google Scholar
• Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst. 1993;85(8):640–647. doi:10.1093/jnci/85.8.640
   PubMedGoogle Scholar
• Jones RB, Shpall EJ, Ross M, et al. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol. 1990;26(2):155–156. doi:10.1007/BF02897264
   PubMed Web of Science ®Google Scholar
• Dahi PB, Lee J, Devlin SM, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021;5(12):2608–2618. doi:10.1182/bloodadvances.2020004167
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood. 2005;105(11):4215–4222. doi:10.1182/blood-2005-01-0035
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi:10.1182/blood-2005-05-2004
   PubMed Web of Science ®Google Scholar
• Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479–1487. doi:10.1016/j.bbmt.2015.04.004
   PubMed Web of Science ®Google Scholar
• Rosenberg E. The 1995 update of recommendations for a standard technique for measuring the single-breath carbon monoxide diffusing capacity (transfer factor). Am J Respir Crit Care Med. 1996;154(1):265–266. doi:10.1164/ajrccm.154.1.8680694
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019.
   Google Scholar
• Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–1410. doi:10.1182/blood-2014-10-604561
   PubMed Web of Science ®Google Scholar
• Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest. 1992;101(5):1257–1264. doi:10.1378/chest.101.5.1257
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Klumpp TR, Magdalinski AJ, et al. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16(12):3796–3802. doi:10.1200/JCO.1998.16.12.3796
   PubMed Web of Science ®Google Scholar
• Bou Akl I, Matar M, Khalil PB, et al. Impact of the conditioning regimen dose intensity before autologous stem cell transplantation on the pulmonary function test abnormalities in patients with lymphoma and multiple myeloma: single center experience. Clin Lymphoma Myeloma Leuk. 2020;20(6):371–376 e1. doi:10.1016/j.clml.2019.10.015
   PubMed Web of Science ®Google Scholar
• Scarlata S, Annibali O, Santangelo S, et al. Pulmonary complications and survival after autologous stem cell transplantation: predictive role of pulmonary function and pneumotoxic medications. Eur Respir J. 2017;49(3):1601902. doi:10.1183/13993003.01902-2016
   PubMed Web of Science ®Google Scholar
• Salloum E, Jillella AP, Nadkarni R, et al. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer. 1998;82(8):1506–1512. doi:10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Seminars in Oncology. 1982;9(1):34–51.
   PubMed Web of Science ®Google Scholar
• Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med. 1977;62(4):608–615. doi:10.1016/0002-9343(77)90424-7
   PubMed Web of Science ®Google Scholar
• Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11(1):1–20. doi:10.1016/S0272-5231(21)00668-7
   PubMed Web of Science ®Google Scholar
• Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone marrow transplantation. 2000;26(10):1107–9.
   PubMed Web of Science ®Google Scholar
• Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am Rev Respir Dis. 1986;133(3):488–505.
   PubMedGoogle Scholar
• Cooper JA, Jr., Matthay RA. Drug-induced pulmonary disease. Dis Mon. 1987;33(2):61–120.
   PubMed Web of Science ®Google Scholar
• Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009;15(11):1447–54.
   PubMed Web of Science ®Google Scholar
• Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;26(10):1107–1109. doi:10.1038/sj.bmt.1702664
   PubMed Web of Science ®Google Scholar
• Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am Rev Respir Dis. 1986;133(3):488–505. doi:10.1164/arrd.1986.133.3.488
   PubMedGoogle Scholar
• Cooper JA, Jr., Matthay RA. Drug-induced pulmonary disease. Dis Mon. 1987;33(2):61–120. doi:10.1016/0011-5029(87)90021-6
   PubMed Web of Science ®Google Scholar
• Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant. 2009;15(11):1447–1454. doi:10.1016/j.bbmt.2009.07.014
   PubMed Web of Science ®Google Scholar
• Crilley P, Topolsky D, Styler MJ, et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplantation. 1995;15(3):361–365.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Dimopoulos M, Smith T, et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol. 1994;68(4):183–188. doi:10.1007/BF01834364
   PubMed Web of Science ®Google Scholar